Last reviewed · How we verify
evolocumab and LDL apheresis
Evolocumab works by binding to PCSK9, a protein that regulates LDL cholesterol levels in the blood, thereby reducing LDL cholesterol production in the liver.
Evolocumab works by binding to PCSK9, a protein that regulates LDL cholesterol levels in the blood, thereby reducing LDL cholesterol production in the liver. Used for Hypercholesterolemia, Homozygous familial hypercholesterolemia.
At a glance
| Generic name | evolocumab and LDL apheresis |
|---|---|
| Sponsor | Hospital General Universitario Gregorio Marañon |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By binding to PCSK9, evolocumab prevents it from returning to the liver, where it would normally stimulate the production of LDL cholesterol. This leads to a decrease in LDL cholesterol levels in the blood, which can help to reduce the risk of cardiovascular events. LDL apheresis, on the other hand, is a procedure that directly removes LDL cholesterol from the blood.
Approved indications
- Hypercholesterolemia
- Homozygous familial hypercholesterolemia
Common side effects
- Injection site reactions
- Musculoskeletal pain
- Nausea
- Diarrhea
Key clinical trials
- Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (PHASE2, PHASE3)
- Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment (PHASE3)
- Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: